IMS site is part of the Informa Markets Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Senior GM Regulatory and Business continuitySun Pharma
Chief Executive OfficerSouth African Health Products Regulatory Authority
RocheLATAM Regulatory Policy Lead
Partner and Deputy Chair, FDA & Life Sciences PracticeKing & Spalding LLP
EVP-Regulatory ComplianceGreenleaf Health and Former FDA
Eisai EuropeSenior Vice President - Global Regulatory, Healthcare Policy and Corporate Affairs
Executive Director - Global Head External Development CollaborationsGenentech/Roche
Associate Director for Science and Communication, Office of Lifecycle Drug Products, OPQ, CDERUS Food and Drug Administration
GMDP Operations Manager and Senior InspectorMedicines and Healthcare Products Regulatory Agency
General Manager - Medicines and Biological ProductsANVISA
Head of GMP Compliance & Aseptic Process IntegrationF Ziel GbmH
PresidentMexican Pharmaceutical Institute
Executive DirectorThe Caribbean Public Health Agency
Director Biosimilar Policy & ScienceMedicines for Europe
PresidentALó ProScience and former Federal Commissioner COFEPRIS - Mexico
Vice President-Regulatory & AccessParexel and Former FDA
Senior Director-Regulatory Affairs CMC Celldex and Former FDA
Partner and Head of UK Life SciencesSidley Austin LLP
FounderBarragan BioConsulting and Former FDA
Principal AuditorMFM GMP Consulting and Former FDA
Deputy Director GeneralEuropean Healthcare Distribution Association
Scientific DirectorGSK Pharmaceuticals, UK
Sr. Vice President – Global Regulatory AffairsAurobindo Pharma
Former VP-Regulatory Affairs, Latin America and CanadaAllergan
Former Regulatory CounselUS FDA
Director – Regulatory AffairCipla
Deputy Chief ExecutiveHealth Products Regulatory Authority
Executive Director-Pharma Regulatory Affairs & Strategic AlliancesCorning Incorporated and Former FDA
Director-Drug Regulatory AffairsBoehringer Ingelheim, Canada
Senior Director-Regulatory CMC/CMOAstraZeneca
Board MemberAlliance for Safe Biologic Medicines
Head-Regulatory & Project ManagementRPG Life Sciences
Executive Vice President - Regulatory AffairsGSK Pharmaceuticals, India
Global Lead, Global Regulatory Policy MSD
Chief Executive OfficerDrug Development and Regulation
Senior GM Regulatory and Business continuity
Chief Executive Officer
South African Health Products Regulatory Authority
Boitumelois the CEO of the South African Health Products Regulator. She has a Ph.D. (Biochemistry) and holds MSc in Management Finance and Investment. She is also a fellow of the African Leadership Initiative. Within the technology innovation space, she was the Executive Director at CSIR Biosciences and prior to that she managed a biotechnology incubator at The Innovation Hub Management Company. She was with McKinsey & Company for 2 years as a McKinsey Leadership Fellow. Prior to that, she was at the CSIR as a Senior Researcher. She completed her postdoctoral research at the University of Nottingham and EPFL, Switzerland.She has published as a first author and co-author in scientific publications, review articles and book chapters. She sits on a number of scientific advisory committees and Board of Directors. She is also involved a number of thought leadership projects such as the African Union Strategy for Health Research, the East Africa Community Bioeconomy strategy development team and WHO Expert Panel on scaling health Innovations in Africa.
LATAM Regulatory Policy Lead
Specialist in Global Health and Health Regulation, with a Master’s Degree in Development and International Cooperation. Broad experience in regulatory policy, both as regulator and industry, leading or contributing to bilateral and multilateral negotiations, harmonization and convergence initiatives. Specialized and policy activities include: working within WHO, PAHO, Mercosur, ICH, IPRP, IMDRF, ICMRA, UNODC, and industry associations; liaising with government agencies, industry and other stakeholders in the area of health regulation; organization of and institutional representation in information sharing events. Currently working in Roche as a Regulatory Policy Lead for Latin America.
Partner and Deputy Chair, FDA & Life Sciences Practice
King & Spalding LLP
Chris Markus focuses on federal and state regulation of drugs, biologics, biotechnology and related
products. As a partner in our FDA and Life Sciences practice and Deputy Practice Group Leader,
Chris represents clients in a range of regulatory strategy and compliance evaluations, enforcement
matters, and business transactions.
Chris represents drug, biologic and other healthcare products companies and investors with
compliance and enforcement under the Food and Drug Administration, the Drug Enforcement
Administration (DEA) and related state agencies such as boards of pharmacy. She also represents
clients in business transactions, including strategic planning, due diligence and assessment, that
involve product development and approval, safety, labeling, marketing and advertising,
manufacturing and supply chain.
Based on her experience, Chris was chosen to serve as the legal member of the Institute of
Medicine's Committee on Pediatric Studies conducted under the Best Pharmaceuticals for Children
Act and the Pediatric Research Equity Act. IOM evaluated studies of drugs and biologics performed
under two statutory regimes that provide incentives and, in some instances, mandate pediatric
research through the drug approval process. The Committee assessed the findings and offered
recommendations and briefings to FDA and the U.S. Congress. Committee findings and
recommendations were considered during the reauthorization of BPCA and PREA in July of 2012.
Chris has been recognized by the BTI Consulting Group as a 2017 "Client Service All-Star" and was
also named a 2016 "Life Sciences Star" by LMG Life Sciences. Chris has also been identified as one
of The Best Lawyers in America for FDA Law, and ranked as a life sciences practitioner by The
Greenleaf Health and Former FDA
Cynthia Schnedar, Executive VP of Regulatory compliance at Greenleaf Health, provides strategic advice to clients in the life sciences industry. She was formerly Director of the Office of Compliance for FDA CDER, where she spearheaded efforts to protect the American public from unsafe and ineffective drug products by ensuring that companies comply with federal standards for quality and safety.
Cynthia previously served at the Department of Justice (DOJ) as Acting Inspector General and in other leadership positions focused on compliance and enforcement issues. Cynthia also served as a prosecutor and a civil trial attorney for DOJ. Cynthia clerked for a judge on the U.S. Court of Appeals for the Ninth Circuit and worked as a television reporter for local stations in New Mexico and Texas. Cynthia earned a B.A. with Distinction from the University of New Mexico and a J.D. with Honors from the University of Texas School of Law.
Senior Vice President - Global Regulatory, Healthcare Policy and Corporate Affairs
David is currently Senior Vice president in Eisai, responsible for Global Regulatory, Government Relations, Public Affairs and Product Safety. After qualifying in medicine, he practised as a physician and cardiologist, with additional interests in metabolic medicine and clinical toxicology. He spent 21 years as a senior regulatory in the UK and Europe. He was executive director of licensing in MCA, CPMP member, chairman of the MRFG and PER committees. He was CEO and Director of the UK Medical Devices Agency and on the creation of the MHRA acting joint chief executive. He worked on secondment at the EMEA /EMA on benefit risk methodologies.
Since 2005 he has worked for Eisai, currently he is also chairman of the ABPI Regulatory Science Committee regulatory committee and a member of the Innovation Board.Within EFPIAhe chairs the Regulatory Committee and sits on the International Regulatory Board.
Chairman of the IFPMA Regulatory Science Committee, a member of the IFPMA Council and of the ICH Committee and General Assembly.
He is a past chairman of the CMR Advisory Board and currently sits as a member of the CIRS Scientific Advisory Council.
Executive Director - Global Head External Development Collaborations
Emma Ramnarine is Global Head of External Development Collaborations at Genentech/Roche, managing the external network for development, manufacturing, and clinical collaborations of Roche’s Biologics and Small Molecules development portfolio. Prior to this, she was the Global Head of Analytical Science and Technology at Genentech/Roche, providing strategic direction and leadership for product control systems lifecycle management, analytical technology innovation and tech transfers. She is also a worldwide-recognized expert on Quality Risk Management (QRM), and continues to provide QRM training to regulatory authorities and at industry forums.
Emma is currently Co-lead for the Industry One-Voice-of-Quality (1VQ) Initiative on Post Approval Changes. This initiative is sponsored by Chief Quality Officers of 20+ global pharma companies who have decided to speak with a unified voice, and develop standard solutions to reduce global PAC complexity.
Emma has 20+ years of global experience in the pharmaceutical, biotechnology and medical device industries in Analytical Science & Technology, Risk Management, Quality Control and Quality Management Systems. She is an Officer on the PDA Board Executive Committee and has led several PDA Task Forces and Technical Reports (TR).
She holds an M.S. in Pharmaceutical Sciences from the University of Connecticut, an M.S. in Medicinal & Pharmaceutical Chemistry, and a B.S. in Pharmacy, both from University of Indore, India.
Associate Director for Science and Communication, Office of Lifecycle Drug Products, OPQ, CDER
US Food and Drug Administration
Commander Geoffrey Wu, Ph.D., PMP, CPH, acting Deputy Director, OLDP, OPQ, joined FDA’s OTR in 2010, has served as research scientist, science staff, chemistry reviewer, special assistant to the Office Director, staff supervisor (Division Director equivalent), Associate Director of Sciences and Communication (ADSC), acting Division Director, and acting Deputy Office Director. He is a scientist officer in the United States Public Health Service. Throughout his FDA tenure, he has been deeply involved, leading or co-leading regulatory review and research for Controlled Correspondence, ANDAs, and supplemental ANDAs and NDAs. Between 2013 and 2017, he served as a founding member on the OPQ Emerging Technology Team (ETT). He was a core member in multiple policy development efforts, such as emerging technology, continuous manufacturing, and comparability protocols. Dr. Wu has training and education in pharmacy, pharmaceutical science, protein chemistry, polymer chemistry, and process analytical technology. He has more than 20 peer-reviewed publications, and been invited to multiple national and international conferences to present or discuss the above related topics. His Ph.D. thesis from the University of Utah focused on self-assembly of hybrid hydrogels containing coiled-coils and drug-free macromolecular therapeutics to induce apoptosis by coiled-coiled mediated crosslinking of antigens.
GMDP Operations Manager and Senior Inspector
Medicines and Healthcare Products Regulatory Agency
Graham co-ordinates the MHRA’s GMP risk-based inspection programme, which has been adapted significantly in response to the challenges of the coronavirus pandemic. Graham specialises in the inspection of sterile product manufacturing as well as the collection, processing and supply of blood and blood components. He also represents the MHRA on the PIC/S Quality Risk Management Expert Circle.
Graham is a Mechanical Engineer (MEng) by training. Prior to joining the MHRA he spent eight years working in the pharmaceutical industry in the areas of human plasma fractionation and sterile product manufacturing, including operational and managerial roles in Validation and Quality Assurance.
General Manager - Medicines and Biological Products
Gustavo Mendes Lima Santos, Specialist in Regulation and Health Surveillance. Safety and Effectiveness Assessment Manager. Therapeutic Equivalence Coordinator at Anvisa. Graduated in Industrial Pharmacy from the University of São Paulo (2001), Specialization in Sanitary Surveillance from FIOCRUZ (2007) and Master in Toxicology applied to Sanitary Surveillance from the State University of Londrina (2013).
Ivo is an Economist with post graduate in Public Administration. He is currently Executive Director and Senior Consultant of Orplavi Consultoria Ltda. A Consulting in the areas of Regulatory Intelligence in the sanitary area, Economy and Market intelligence in the area of health.
Earlier Ivo was Director at the ANVISA from 2013 to 2016. Executive Secretary of the Inter-ministerial Chamber of Economic Regulation of the Medicine Market (CMED) – ANVISA.-2011-2013 and Head of Cabinet of the Ministry of Environment. of Brazil- 2008-2010
Head of GMP Compliance & Aseptic Process Integration
F Ziel GbmH
PHSS: Pharmaceutical & Healthcare Science Society Head of Aseptic processing and ATMP Special interest group plus co-lead of Annex 1 & Contamination Control Strategy (CCS) Focus group.
James is based in the UK with a global support role at F Ziel (Germany) who manufacture technologies for environmental control in sterile pharmaceuticals & ATMP manufacturing. Together with the role at F Ziel James is the former Chairman (10 years) and current elected Head of the Not-for-Profit PHSS: Pharmaceutical & Healthcare Sciences Society Aseptic processing and ATMP special interest group and Co-lead of the EU GMP Annex 1 and Contamination Control Strategy (CCS) Focus group. Working experience includes 10 years in radio pharmaceutical manufacturing (Amersham-GE Healthcare) and over 30 years working in sterile medicinal product manufacturing support where increasingly aseptic processing applies to ATMPs, particularly Gene and Cell therapies. James is a qualified pharmaceutical process engineer with addition education in pharmaceutical microbiology and a subject matter expert in Barrier Technology (Isolators and RABS) and Bio-decontamination with Hydrogen peroxide vapour (H202-VHP). James is also a Member of ISPE and Pharmaceutical Quality Group UK (PQG).
Mexican Pharmaceutical Institute
Co-founder and President of the Pharmaceutical Institute (INEFAM: LATAM®), since 2006.
He graduated Master in Business Administration (MBA) from Tulane University in 2006. His experience in the pharmaceutical industry began at Eli Lilly México, when he was in charge of various strategic marketing and project management positions from 1999 to 2005. Previously, he had been an alternate deputy of the Local Congress of Nuevo León at the age of 23, which led him to know in depth the law and procurement processes and the entire legal framework related to the right to health.
To date, he continues to be an advisor to the Health, Anti-Corruption and Transparency Commissions, both for Deputies and Senators, in pro-bono activity, as he aspires for the health system to resume the path that has been abandoned during the current federal administration in México.
José Carlos is a keynote speaker at various international congresses, and has given more than 100 conferences, highlighting his extensive command of several languages. Of the main conferences he has given, his participation in the Open Parliament of the Chamber of Deputies stands out, on July 27, 2020, with the presentation "Comparative Active Transparency 2018 versus 2019 - Results of Submitting 10,000 Transparency requests per year", as well as a plenary session on the biosimilars market in Mexico and LATAM at Harvard Medical School in October 2018, for over 500 attendees and delegates from different countries.
He is a member of the board of directors of SOHIN, one of the most promising companies in the healthcare provider sector.
His differentiating expertise lies in the understanding of field procedures and strategies, in medical units, developing complex strategies to increase average consumption and authorized consumption at the hospital, delegation, and national levels.
In his academic activity, he is the creator of the philosophy of "Inventory Based Medicine", where he justifies that the Physician in Mexican government institutions can only prescribe what he can (national formularies, included and authorized), and what there is on inventory (must be available at the pharmacy at the time of prescription), as well as "The 6 Jobs of the Government Sales Forces", as a way to differentiate and land the work of KAM's and KAE's. He has also innovated with his very peculiar technique of therapeutic substitution analysis by NFC.
His international experience extends to being a nomad who has lived in the CDMX, MTY, Puerto Rico, Bucharest and Sao Paulo, which has led him to have an extensive domain of 4 languages, although he assures that he can read in 6. He loves wines, he considers himself a wine connoisseur.
The Caribbean Public Health Agency
Dr St John rose in the ranks of Public Health in Barbados from 1994 to become the first Barbadian Chief Medical Officer of Barbados in 2005. Dr St John held the position of International Health Regulations Focal Point, Liaison Officer for IAEA for Barbados and sat on the QEH Board, the NCD Commission and the Board of the Barbados Water Authority, among many.
Dr St John also represented Barbados on the Executive Board of WHO and then became the first Caribbean person to Chair the Executive Board from 2012 to 2013.
Dr St John had two stints with other organizations during the twelve years she was the CMO. She was a Senior Advisor with WHO, supporting the co-facilitators of the UNGA Review of the High-Level Summit on NCDs in 2014, then she was the Director of Surveillance, Disease Prevention and Control at CARPHA from October 2015 to August 2016 until she left finally left the post of CMO in 2017 when she became the Assistant Director General at the WHO HQ in Switzerland. There she held the Portfolio of Climate and Other Determinants of Healthand successfully completed the first phase of the Climate Change and Health SIDS Initiative.
In July 2019 Dr St John became the Executive Director of the Caribbean Public Health Agency. There she hassteered CARPHA through a CARICOM Evaluation, selected new Directors, improved the governance and accountability frameworks of CARPHA, as well as focused on strengthening CARPHA’s resource mobilization and partnership portfolios.
CARPHA has led the public health response to the COVID-19 pandemic and Dr St John’s leadership has seen her have over 100 speaking engagements as she engages with multiple sectors, andthe Health leaders and Heads of Government in CARICOM.
Director Biosimilar Policy & Science
Medicines for Europe
Julie has been leading the Biosimilar Medicines Group, a sector group of Medicines for Europe since 2015. Her work consists in creating and nurturing partnerships with experts in (bio)pharmaceuticals and across healthcare systems, balancing interests for a resilient and sustainable healthcare framework. The main objectives of the biosimilar medicines group are to support and facilitate the design, evolution and implementation of policies aimed at creating efficiency gains thanks to biosimilar medicines use and greater access to health services and products for all patients. Since January 2019 on, she has been the co-chair of the Biosimilars committee of the International Generic and Biosimilar medicines Association (IGBA) focusing on convergence of global policies and standards. Her knowledge and understanding of the scientific, regulatory and health policy environment at EU and international levels, as well as of the functioning of the EU ecosystem, greatly supports her effective engagement with all the players involved. Part of the Medicines for Europe Management Team, she is responsible for the People & Organisation matters, focused on employees professional growth.With a MSc in Pharmacology, she previously worked in the pharmaceutical industry.
ALó ProScience and former Federal Commissioner COFEPRIS - Mexico
Mr. Julio Sánchez y Tépoz is a Mexican Lawyer with more than 20 years experiencein regulatory agencies in the Mexican Government. He is an expert in sanitary andhealth affairs; for 8 years he worked at the Mexican Sanitary Agency, the FederalCommission for the Protection against Sanitary Risk, COFEPRIS.
Mr. Sánchez y Tépoz holds a law degree from Escuela Libre de Derecho in Pueblaand studied a master’s degree in Economic Development from UniversidadComplutense in Madrid, Spain. He has several specialized studies in sanitary affairs,foreign trade, health regulation, economics, competition policy, research onmonopolistic practices, growth and competitiveness, foreign investment, legalargumentation, applied intelligence, advertising, among others.
He was appointed Head of COFEPRIS by the Mexican President in 2016 and actedas such until December 2018. Mr. Sánchez y Tépoz initially joined COFEPRIS in 2011as Chief of Staff of the Federal Commissioner and on July 2012 he becameCommissioner of Health Promotion.
During his time in COFEPRIS, he coordinated and directed several strategies focusedon the improvement of access to quality medicines in the public and private market. During his work in COFEPRIS he was appointed as Vice President of the InternationalCoalition of Medicines Regulatory Authorities (ICMRA) for the Period 2017-2018,where he participated on facilitating greater co-operation and to enable Heads ofMedicines Regulatory Authorities to exercise collective and concerted strategicleadership over existing and new international initiatives and enablers, as well as overshared regulatory issues and challenges.
Mr. Julio Sánchez y Tépoz currently presides over the international nonprofit academicorganization AlóProScience, a Latin American Association of Regulatory AffairsProfessionals focused on promoting Good Regulatory Practices and Regulatory Policyin the region while training and educating regulatory professionals. He also teachesHealth Protection Law class at the Mexican National Autonomous University (UNAM)and gives regulatory assistance to the private and public sector on Mexican sanitaryand health topics.
He has also worked in various institutions of the Mexican Federal Governmentincluding the Federal Competition Commission, the Federal Consumer ProtectionAgency (PROFECO), the Attorney General´s Office of the Mexican Government,where he performed legal analysis and was involved in international cooperation withEurope, Latin America, the UN, and other specialized organizations.
In 2020 Julio Sánchez was elected as member of the Board of Trustees of the UnitedStates Pharmacopeia, for the period 202-2025. In the same year Mr. Julio Sánchez yTépoz became Partner of Health Sanitary Consulting, a specialized firm on legal andregulatory services across North and Latin America.
Vice President-Regulatory & Access
Parexel and Former FDA
Acts as a trusted advisor for business solutions addressing specific client needs using expertise in CMC regulatory, bioprocess technology, biotech risk assessment and mitigation and compliance.
Senior CMC coach and subject matter expert for project teams for multiple clients and projects.
Over 30 years of experience in biotech and biomedical science in NIH, FDA and Parexel, including industry standards ideation and creation and technical report building
Supported FDA Office of Biotechnology Products as part of the product quality (CMC) review team
Novel Biologics, Biosimilars, Transition Products, and Drug-Device Combination Products
Extensive FDA review experience with 351(a) and 351(k) BLA pathways, CMC and Inspections
Widely considered to be a world-class expert in viral safety risk assessment and mitigation for biopharmaceuticals; organizing international conferences and technical task forces
Currently helping multiple clients mapping out regulatory strategies for biotech drug and drug-device combination candidates ranging from pre-IND to NDA/BLA stages in multiple therapeutic areas.
Postdoctoral Fellow, National Institute or Allergy and Infectious Disease, NIH, Bethesda MD
Ph.D., California Institute of Technology, Pasadena CA
B.A. Biology, University of Chicago, Chicago IL
Senior Director-Regulatory Affairs CMC
Celldex and Former FDA
Mamta Gautam-Basak spent 20+ years with the Food and Drug Administration (FDA) working in various scientific, CMC, and regulatory roles primarily within the Center for Drug Evaluation and Research (CDER). She is excited to help the next generation of biotech and pharmaceutical entrepreneurs understand the complexities of drug development regulation so that they can build proactive strategies into their growth plans as early and efficiently as possible.
She is fluent in all aspects of the regulatory process in drug development and has seen what happens when companies miss critical requirements and details. She is excited to share her thoughts with biotech and pharma entrepreneurs on their plans to bring critically-needed therapeutics to market in a safe and compliant way.
Mamta currently serves as a senior technical advisor for US Pharmacopeia’s Promoting the Quality of Medicines (PQM+) program, a USAID-funded initiative that helps low- and middle- income countries improve the systems that ensure the quality of and increase the supply of priority medicines. She provides technical oversight and direction to all global implementation activities related to regional and country regulatory systems. She earned her PhD in analytical chemistry from the Indian Institute of Technology-Delhi.
Partner and Head of UK Life Sciences
Sidley Austin LLP
Maria Isabel Manley leads Sidley’s Life Sciences team in London and is a distinguished thought leader and adviser on EU and UK regulatory law. She advises on a broad spectrum of matters, both contentious and non-contentious, including IP regulatory rights, market access, advertising, product liability and competition; as well as on issues relating to Brexit. She has represented a number of the world’s leading pharmaceutical companies in landmark cases before the EU and English Courts, as well as before the regulatory authorities, including the European Commission, the European and UK medicines authorities (EMA and MHRA), the National Institute for Health and Clinical Excellence and the Department of Health.
Marie is the co-author of “Navigating European Pharmaceutical Law,” Oxford University Press, 2015. Most recently, she has been listed in Best Lawyers 2020 for Life Sciences Law and has been awarded Best in Life Sciences at the LMG Europe Women in Business Law Award 2019. Sidley were also awarded Law Firm of the Year for FDA Law by the U.S News – Best Lawyers 2020.
Barragan BioConsulting and Former FDA
Dr. María José (Pepa) López-Barragán is a former U.S. FDA (CDER) regulator and founder of BarragánBioConsulting, a company that offers consulting services to pharmaceutical companies globally. Pepa has 16 years of combined experience in regulatory affairs (CMC), facility compliance, and multiple aspects of drug development and research. While serving at the FDA, she participated in the approval of 15 original and biosimilar biologic license applications and was responsible for the product quality assessment of over 200 regulatory submissions and nearly 20 facility inspections in 8 countries. Pepa was recipient of two FDA special recognition awards for her contributions to BLA assessments and the facility inspectorate team. Prior to serving at the FDA, Pepa was Principal Scientist at GlaxoSmithKline and GeneDx and co-authored 20 peer-reviewed scientific publications and one biotechnology patent. Pepa holds a PhD in Biochemistry and Molecular Biology by Complutense University (Madrid, Spain) and completed a 5-year postdoctoral research program at the U.S. National Institute of Allergy and Infectious Diseases, Bethesda, MD.
MFM GMP Consulting and Former FDA
Experienced former US FDA Drug Specialist with a demonstrated history of working extensively in the pharmaceuticals industry in the US and multiple other countries including: China, India, Germany, Italy, Austria, Ireland, France, the UK and the Netherlands to name a few.
Now putting those skills to work as the owner of her own consulting firm providing insight into the workings of the US FDA through: training, conducting Mock FDA audits, advising on facility set up and layouts and advising on the preparation of responses to FDA-483's and Warning Letters.
Skilled at auditing a wide variety of manufacturers of: Sterile and non-sterile API's, Sterile and Non-Sterile Finished products, Immediate release, Extended release and Timed release Capsules and Tablets, Good Laboratory Practice (GMP) Labs, Good Laboratory Practice (GLP) Lab facilities, Biologically produced APIs and Finished Products and Medical Device manufacturers. With wide experience evaluating and improving documentation in relation to: Change Control, Deviations, Complaints, Investigations and CAPA as well as laboratory documents, raw data and OOS investigations. Well versed in Pharmaceutical, Biotechnology, and Regulatory Requirements.
Deputy Director General
European Healthcare Distribution Association
Martin is the Deputy Director General for the European Healthcare Distribution Association (GIRP). Martin duties include day to day management, supporting the implementation of the strategic and policy decisions of the associations governing bodies, dealing with the association relations with its member organizations, authorities and other stakeholders. With a legal background he also deals with the broad range of legislative and regulatory issues affecting the pharmaceutical full-line wholesalers as healthcare distributors in Europe.
GIRP is the umbrella organization of pharmaceutical full-line wholesalers in Europe. It represents the national associations of over 750 healthcare distributors and pharmaceutical full-line wholesalers serving 33 European countries, including major pan-European pharmaceutical full-line wholesaling companies
GSK Pharmaceuticals, UK
Mike Urquhart (Ph.D.) has over 20 years’ experience within the Pharmaceutical industry, working mainly in process development as a synthetic organic chemist. Since starting at GlaxoSmithKline (GSK), Mike has had positions of increasing responsibility ranging from lab chemist and team manager through to Chemistry Manufacturing and Control (CMC) project manager. During his GSK career, Mike has led the primary development / delivery of 10 products, spanning early through to late phase development. Mike’s current rolesare co-chair of the Impurities Oversight Panel, where he is a GSKmutagenic impurity risk assessment subject matter expert and Scientific Director as well as the GSK Drug Substance nitrosamine risk assessment lead for small molecules. Mike also represents GSK on the Lhasa Mirabilis Pharmaceutical Consortium and presents externally on best practice for mutagenic impurity control strategies for pharmaceutical products.
Sr. Vice President – Global Regulatory Affairs
Former VP-Regulatory Affairs, Latin America and Canada
Paula carries 30 years of experience in the pharmaceutical industry working in US and EU multinational companies such as Allergan (Abbvie), Hoechst (Sanofi) and Syntex (Roche).Career developed in Research and Development, Regulatory Affairs, Safety, Quality and Technology at Latin America and Canada with close interface with Europe, USA and Asia markets. She has deep knowledge in biologics, drug products, medical devices, combinations, implants, and electromedical equipment. Her experience is in product development from strategy, development, clinical operations, registration, pricing, market access and launch. With solid relationships with Regulatory Agencies, Key Opinion Leaders, External Trade Associations she has been worked to shape the regulatory environment at emerging markets for existing and new technologies including support for the creation of new standards. Strong experience in regulatory inspections, conductingtraining and qualification programs for internal teams and suppliers.
Paula is a Pharmacist, Master in Pharmaceutical Sciences, and MBA in Project Management.
Former Regulatory Counsel
Mr. Crooker is a valuable, scientifically trained drug development attorney with a highly desirable combination of U.S. Food and Drug Administration (FDA) and private sector experience in global large-cap, mid-size specialty and closely held pharmaceutical and biotechnology companies. Mr. Crooker has accumulated extensive global professional and practice experience for 21 years in applying laws, regulations, and policy to successfully solve complex problems confronting pharmaceutical and biotechnology firms engaged in all stages of product development; chemistry, manufacturing and controls (CMC) and product quality strategy; the regulatory approval process and health authority engagement; product commercialization and lifecycle management; and drug manufacturing compliance and enforcement for both conventional commercial manufacturers and compounding pharmacies.
Mr. Crooker readily identifies, analyzes and capably resolves complex legal, regulatory, and technical issues in a high risk and heavily regulated environment. Mr. Crooker has a proven record of effectively counseling and communicating with organizations on the analysis of issues at the interface of product development and commercialization, regulation, and business; creating successful technical, regulatory and compliance strategies for all stages of pharmaceutical product lifecycle management; assessing and integrating new product acquisitions; and leading and growing business functions
He has presented at numerous meetings for the American Association for Pharmaceutical Scientists (AAPS) and participates in the International Society of Pharmaceutical Engineering (ISPE), the Food and Drug Law Institute (FDLI) and the American Society for Testing and Materials (ASTM).
Mr. Crooker holds an undergraduate degree in chemistry and a law degree. He remains an active member of the California Bar and has also been admitted to the U.S. District Court for the Central District of California.
Director – Regulatory Affair
Dr. Praveen Kumar is currently working as Directory of Regulatory Affairs at Cipla, heading Medical Devices, India Regulatory, Regulatory Assurance and Data Systems functions. He has around 20+ years of Healthcare Regulatory and Quality experience in Combination Products, Medical Devices, Pharma, BioPharma including research experience.
Deputy Chief Executive
Health Products Regulatory Authority
Rita Purcell is the Deputy Chief Executive at the Health Products Regulatory Authority where she has responsibility for international affairs, finance, legal, regulatory affairs, corporate governance and infrastructure. She has lead on a number of international initiatives and is an active participant in the International Coalition of Medicines Regulatory Authorities (ICMRA). Rita is the alternate member of the Board of the European Medicines Agency andis on the Council of the Pharmaceutical Society of Ireland, the regulator of pharmacies and pharmacists. Since 2016 Rita has lead the internal HPRA Brexit Task Force and represents the management team for Brexit coordination and planning at national government leveland leads HPRA’s engagement with the European network and stakeholders in Brexit preparations. She read law at University College Dublin and is qualified as a Chartered accountant. She previously worked for Price Waterhouse in Dublin and San Francisco and also has worked in the construction and food industries in the areas of finance, acquisitions and internal audit.
Executive Director-Pharma Regulatory Affairs & Strategic Alliances
Corning Incorporated and Former FDA
Robert (Bob) Guidos, J.D. serves as executive director of pharmaceutical regulatory affairs and strategic alliances for Corning Incorporated. Guidos joined Corning in 2017 after serving as senior advisor to the director of the U.S. Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER) and as CDER’s associate director for legislative affairs. Based in Washington, DC, he directs Corning’s government affairs’ global policy and strategy in support of its life sciences technologies divisions. In 2020, Guidos helped launch Corning’s strategic response to the SARS-CoV-2 pandemic by assisting in securing a $204M award from the U.S. Biomedical Advanced Research and Development Authority (BARDA) to accelerate manufacture of Corning’s innovative pharmaceutical glass vials for use with COVID-19 vaccines. As a health policy executive with 27+ years experience with the FDA, U.S. Congress and the Infectious Diseases Society of America (IDSA), he has successfully led strategic initiatives by mobilizing multidisciplinary teams of experts in medicine, science, public health, law, regulation, and government and public relations. Guidos received his juris doctor degree from the University of Pittsburgh School of Law and bachelors in chemistry and business from Gannon University in Erie, Pennsylvania.
Director-Drug Regulatory Affairs
Boehringer Ingelheim, Canada
Samar began her career in basic research in private and hospital settings, before transitioning to Regulatory Affairs. Currently, Samar is the Director of Regulatory Affairs at Boehringer-Ingelheim (Canada) Ltd., a global family owned Pharmaceutical Company. Samar’s proficiency includes over 26 years of experience in progressive roles in the Pharmaceutical Industry, with more than 18 years of proven strategic leadership and people management skills, motivating various teams in different functions to deliver high quality results in line with business priorities.
She graduated from the University of Western Ontario with a Master of Science degree in Molecular Biology, and most recently completed her Executive Master of Business Administration degree from the Ivey Business School in London, Ontario, Canada.
Senior Director-Regulatory CMC/CMO
Sarah Pope Miksinski has been with AstraZeneca since February 2018 and is currently a Senior Director in Regulatory CMC, AstraZeneca. Her duties include leadership of a global team covering CMC regulatory strategy for development and pre-approval health authority submissions, as well as serving as a key contributor to several ongoing initiatives including continuous manufacturing and Q12 implementation. She represents AstraZeneca in various external capacities – including serving with Tony Mires-Sluis on PhRMA’s Global Quality and Manufacturing Committee, serving as chair of ISPE’s Regulatory Steering Council, and supporting multiple other advocacy efforts.
At the time of her departure from FDA, she was the head of two offices in FDA’s Office of Pharmaceutical Quality – serving permanently as the director of the Office of New Drug Products (2014-2018) and simultaneously serving as the interim director of the Office of Surveillance (2016-2017). Collectively, both roles placed her in OPQ’s senior leadership team for several years, where she contributed heavily to OPQ’s strategic direction including numerous recent quality review, communications, and GMP/inspectional efforts. On behalf of FDA, she also played a key role in FDA/nonprofit interface discussions (e.g. PhRMA, ISPE, AAM) and in development of international strategy and related ICH proposals.
Sarah began her FDA career in 2002 and served as a primary, secondary and tertiary reviewer before being selected as a senior management official. Prior to joining FDA, she completed a postdoctoral fellowship at the National Institute of Health. She is trained as an organic chemist and possesses a PhD in organic chemistry (Oklahoma State University, 1999). She also has a B.A. in chemistry (Earlham College, 1994).
In her free time, Sarah greatly enjoys spending time with her husband (Ted) and their son (Adam). She is an avid musician and enjoys skiing and oil painting.
Alliance for Safe Biologic Medicines
Stephen lives in Scotland and is a member of the International Advisory Board of the Alliance for Safe Biologic Medicines (USA) and speaks on patient, prescriber and pharmacist perspectives of biosimilars. Since 2006 his career has been in public health. Initially as CEO of Cystic Fibrosis Victoria, with several national and international committee & board roles. In recognition of his work, he was made an Honorary Life Member of the Australian peak patient body (2014) and later elected to Fellowship of the Royal Society for Public Health (2021).
Prior to 2006, Stephen was Vice President of Swinburne University of Technology. Before Swinburne, he was Foundation Head of Continuing and Community Education at the, now, Open University of Hong Kong (1992-95). His career in education started in 1979 and was varied, diverse and fast moving. In 2001 I became a Life Fellow of the Royal Society for Arts and a Life Member of the Graduate Union of the University of Melbourne.
Head-Regulatory & Project Management
RPG Life Sciences
Suchitra has a varied experience of around 29 years in Pharma Industry out of which 20 years in Regulatory Affairs function with Global Regulatory filings.
Her gamut of experience spans from hands on Regulatory experience for API & Formulations filings into Regulated & Semi-regulated markets such as USA, EU, and ANZ to ASEAN, African & LATAM countries resulting into many ANDAs, MAs, DMFs, CEPs to the credit.
In a career span of more than 29 years, worked in different companies’major ones are J.B. Chemicals & Pharmaceuticals Ltd., Nicholas (I) Ltd., JK Pharmaceuticals. etc. at different capacities in different functions such as R&D, Quality and in Regulatory affairs. Last 20 years exclusively been working in Regulatory Affairs function out of which last 12 years in heading the dept.
At RPG Life Sciences Ltd working as Head – Regulatory & Project Management and responsible for various technical/ regulatory decisions and strategies.
Experience also covers as handling inspections with Regulatory authorities such as MHRA, USFDA,EU authorities, TGA, and various overseas eminent pharma companies. Travelled abroad on various official responsibilities.
Suchitra has completed B. Pharm from UDCT (now known as ICT- Mumbai) & an alumni of IIM- Calcutta for completing Executive program in Senior Management.
Executive Vice President - Regulatory Affairs
GSK Pharmaceuticals, India
Global Lead, Global Regulatory Policy
Drug Development and Regulation
Independent consultant, he founded DDR (Drug Development and
Regulation, www.ddrmedic.com), located in Barcelona, Amsterdam and
London, where he is the CEO and Senior Consultant. DDR provides highquality
regulatory assistance to companies and institutions developing
drugs and medical devices.
He was Head of Safety and Efficacy of Medicines at the European Medicines
Agency (EMA) during 2005-2012, and previously held leadership positions
in the biopharmaceutical industry for more than eighteen years, covering
international clinical development, drug safety, pharmacovigilance,
biostatistics and medical affairs.
In addition to Dr. Luria’s specialty in internal medicine, and pharmaceutical
medicine and biostatistics (University Autonomous Barcelona), he has
developed expertise in several specific therapeutic areas, carried out
postgraduate qualification in clinical pharmacology, drug development and
regulation (Tufts University School of Medicine, Boston), and he is a
recognized expert on regulatory systems and benefit-risk assessment
(modelling, development and methodologies).
Furthermore, he is member of the Board of Directors of the IFAPP-King’s
College Postgraduate Course, Senior Visiting Lecturer at the King’s College
in London and lecturer at several other academic institutions in Europe and
He is currently member of the advisory board of several biopharmaceutical
and medical devices companies and serves as consultant and regulatory
service provider to many others in Europe, Japan, US, Australia, Israel and